RIL
ZYNE

Rothschild Investment LLC’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Rothschild Investment LLC’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-16,450
Closed -$160K – 386
2018
Q2 		$160K Sell
16,450
-2,170
-12% -$22.2K 0.02% 358
2018
Q1 		$162K Sell
18,620
-9,850
-35% -$106K 0.02% 360
2017
Q4 		$356K Hold
28,470
– – 0.04% 311
2017
Q3 		$238K Sell
28,470
-28,600
-50% -$302K 0.03% 366
2017
Q2 		$968K Buy
57,070
+11,450
+25% +$228K 0.11% 205
2017
Q1 		$917K Buy
45,620
+22,225
+95% +$442K 0.11% 205
2016
Q4 		$365K Buy
+23,395
New +$315K 0.04% 314

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FTIOP
Fiduciary Trust International of Pennsylvania Radnor, Pennsylvania $2.14B AUM 3.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Rothschild Investment LLC's ZYNE Position: Q3 2018 in Review

Rothschild Investment LLC sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2018, closing a stake of 16,450 shares — an estimated $160K sold.

Rothschild Investment LLC first reported a position in ZYNE in Q4 2016 and held it in 7 quarters. The position peaked at $968K in Q2 2017. 66 funds tracked by Wall St. Rank hold ZYNE as of Q3 2018.

  • Rothschild Investment LLC reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2018 after selling out during the quarter.
  • Rothschild Investment LLC sold 16,450 Zynerba Pharmaceuticals, Inc shares in Q3 2018, an estimated $160K.
  • Rothschild Investment LLC first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2016 and held it in 7 quarters.
  • Rothschild Investment LLC's Zynerba Pharmaceuticals, Inc position peaked at $968K in Q2 2017.
  • 66 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2018.

Based on Rothschild Investment LLC's 13F filing for Q3 2018, filed 17 Oct 2018.